<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6166">
  <stage>Registered</stage>
  <submitdate>10/08/2016</submitdate>
  <approvaldate>10/08/2016</approvaldate>
  <nctid>NCT02870972</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema</studytitle>
    <scientifictitle>A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BCX7353 as a Preventative Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema</scientifictitle>
    <utrn />
    <trialacronym>APeX-1</trialacronym>
    <secondaryid>BCX7353-203</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hereditary Angioedema (HAE)</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BCX7353
Treatment: drugs - Placebo

Experimental: Part 1: BCX7353 350 mg once daily - BCX7353 capsules, 350 mg dose administered once per day for 28 days

Experimental: Parts 2 and 3: BCX7353 250 mg once daily - BCX7353 capsules, 250 mg dose administered once per day for 28 days

Experimental: Parts 2 and 3: BCX7353 125 mg once daily - BCX7353 capsules, 125 mg dose administered once per day for 28 days

Placebo Comparator: Parts 1, 2 and 3: Placebo - Placebo capsules, administered once per day for 28 days

Experimental: Part 3: BCX7353 62.5 mg once daily - BCX7353 capsules, 62.5 mg dose administered once per day for 28 days


Treatment: drugs: BCX7353
Plasma kallikrein inhibitor

Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of confirmed HAE attacks</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence and severity of adverse events and laboratory abnormalities</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life, as measured by the Angioedema Quality of Life Questionnaire</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life, as measured by the Depression, Anxiety, Stress Scales (DASS) questionnaire</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentrations of BCX7353 at steady state</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  A clinical diagnosis of HAE type I or II

          -  Documented HAE attacks within a defined calendar period

          -  Access to acute attack medications

          -  Sexually active women of child-bearing potential and sexually active men must utilize
             effective contraception

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Women who are pregnant or breast-feeding

          -  Any clinical condition or medical history that would interfere with the subject's
             safety or ability to participate in the study

          -  Use of C1INH, androgens or tranexamic acid for prophylaxis of HAE attacks

          -  History of or current alcohol or drug abuse

          -  Infection with hepatitis B, hepatitis C or HIV

          -  Participation in any other investigational drug study currently or within the last 30
             days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>75</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Campbelltown</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Campbelltown</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Salerno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <state>Skopje</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brimingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BioCryst Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This 3-part study will evaluate the safety and efficacy of an oral treatment, BCX7353, in
      preventing angioedema attacks in subjects with hereditary angioedema (HAE). In Part 1 of the
      study, eligible subjects will be randomized to receive oral BCX7353 or placebo for 4 weeks.
      Assuming successful completion of Part 1, additional subjects will be randomized in Part 2 to
      one of 2 lower doses of BCX7353 or placebo. Part 3 will enroll additional subjects into one
      of three doses of BCX7353 or placebo. The study will compare the number of acute attacks in
      each treatment group, as well as a number of other clinical and pharmacologic outcomes, and
      the safety and tolerability of each dose of BCX7353 compared to placebo.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02870972</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Emel Aygören-Pürsün, MD</name>
      <address>University Hospital Frankfurt Goethe University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>